Zacks Research Issues Optimistic Forecast for CLB Earnings

Core Laboratories Inc. (NYSE:CLB) – Equities research analysts at Zacks Research increased their Q4 2027 EPS estimates for shares of Core Laboratories in a research report issued to clients and investors on Wednesday, August 19th. Zacks Research analyst Team now expects that the oil and gas company will post earnings of $0.24 per share for the quarter, up from their previous estimate of $0.23. The consensus estimate for Core Laboratories’ current full-year earnings is $0.56 per share. Zacks Research also issued estimates for Core Laboratories’ Q1 2028 earnings at $0.11 EPS.

Several other equities analysts have also commented on the stock. Weiss Ratings raised shares of Core Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, August 3rd. Johnson Rice upgraded Core Laboratories from a “hold” rating to a “buy” rating and set a $21.00 price objective on the stock in a report on Thursday, August 13th. Finally, Wall Street Zen raised shares of Core Laboratories from a “sell” rating to a “hold” rating in a research report on Saturday, August 1st. One research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $21.00.

Core Laboratories Stock Performance

NYSE CLB opened at $12.29 on Friday. The company has a current ratio of 2.12, a quick ratio of 1.55 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $563.87 million, a PE ratio of 21.95, a price-to-earnings-growth ratio of 2.91 and a beta of 1.03. The business’s 50-day moving average price is $11.53 and its 200 day moving average price is $14.47. Core Laboratories has a twelve month low of $9.79 and a twelve month high of $20.36.

Core Laboratories (NYSE:CLB) last announced its quarterly earnings data on Wednesday, July 29th. The oil and gas company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.02. The business had revenue of $124.61 million for the quarter, compared to the consensus estimate of $126.26 million. Core Laboratories had a net margin of 5.10% and a return on equity of 10.03%. The company’s quarterly revenue was down 4.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.19 earnings per share. Core Laboratories has set its Q3 2026 guidance at 0.120-0.200 EPS.

Core Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Monday, August 10th will be paid a dividend of $0.01 per share. The ex-dividend date of this dividend is Monday, August 10th. This represents a $0.04 annualized dividend and a yield of 0.3%. Core Laboratories’s payout ratio is 7.14%.

Insiders Place Their Bets

In other Core Laboratories news, CEO Lawrence Bruno bought 5,000 shares of the stock in a transaction dated Friday, July 31st. The stock was bought at an average cost of $10.78 per share, for a total transaction of $53,900.00. Following the completion of the purchase, the chief executive officer directly owned 262,438 shares of the company’s stock, valued at approximately $2,829,081.64. The trade was a 1.94% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 1.26% of the stock is currently owned by insiders.

Institutional Trading of Core Laboratories

Hedge funds have recently made changes to their positions in the stock. CWM LLC lifted its holdings in shares of Core Laboratories by 36.1% in the fourth quarter. CWM LLC now owns 2,516 shares of the oil and gas company’s stock valued at $40,000 after buying an additional 668 shares during the period. Platinum Investment Management Ltd. lifted its stake in Core Laboratories by 3.9% during the third quarter. Platinum Investment Management Ltd. now owns 23,758 shares of the oil and gas company’s stock valued at $294,000 after buying an additional 889 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of Core Laboratories by 6.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 17,932 shares of the oil and gas company’s stock valued at $207,000 after acquiring an additional 1,040 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Core Laboratories by 4.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,893 shares of the oil and gas company’s stock valued at $418,000 after purchasing an additional 1,170 shares in the last quarter. Finally, Quarry LP boosted its position in Core Laboratories by 118.1% during the 3rd quarter. Quarry LP now owns 2,953 shares of the oil and gas company’s stock worth $36,000 after acquiring an additional 1,599 shares during the period. Institutional investors and hedge funds own 97.81% of the company’s stock.

About Core Laboratories

Core Laboratories N.V. is a global provider of proprietary and patented reservoir description and production enhancement services to the oil and gas industry. The company applies specialized expertise in core and fluid analysis, advanced petrophysical interpretation, and reservoir engineering to optimize hydrocarbon recovery. By integrating laboratory testing with field services and digital analytics, Core Laboratories delivers insights that help operators maximize production and extend the life of their assets.

The company’s portfolio spans two primary service lines: reservoir description and production enhancement.